{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:39Z","timestamp":1790916819511,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":111,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101229","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:39:01Z","timestamp":1776901141000},"page":"101229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed\/refractory acute myeloid leukemia in Mexico"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-9345","authenticated-orcid":false,"given":"Andr\u00e9s G\u00f3mez","family":"De Le\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8600-1751","authenticated-orcid":false,"given":"Jamie Jung-Hee","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0143-9928","authenticated-orcid":false,"given":"Georgia","family":"Gourgioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4582-6896","authenticated-orcid":false,"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-9042","authenticated-orcid":false,"given":"Juan Guillermo","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-8864","authenticated-orcid":false,"given":"Li-Jen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2026.101229_bib0001","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101229_bib0002","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101229_bib0003","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101229_bib0004","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/j.clml.2019.12.015","article-title":"Acute myeloid leukemia in Mexico: the specific challenges of a developing country. Results from a multicenter national registry","volume":"20","author":"Demichelis-G\u00f3mez","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101229_bib0005","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101229_bib0006","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/10428194.2018.1504937","article-title":"Management of primary refractory acute myeloid leukemia in the era of targeted therapies","volume":"60","author":"McMahon","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101229_bib0007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101229_bib0008","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101229_bib0009","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.arcmed.2016.06.003","article-title":"Prevalence and clinical significance of FLT3 mutation status in acute myeloid leukemia patients: a multicenter study","volume":"47","author":"Cuervo-Sierra","year":"2016","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ctarc.2026.101229_bib0010","unstructured":"Consulta de Registros Sanitarios (COFEPRIS), Rydapt\u00ae (midostaurin) 25.00 mg capsule [Health Registry Data], Sandoz GmbH, 2018. Available from: https:\/\/tramiteselectronicos02.cofepris.gob.mx\/BuscadorPublicoRegistrosSanitarios\/BusquedaRegistroSanitario.aspx Accessed April 28, 2026."},{"key":"10.1016\/j.ctarc.2026.101229_bib0011","unstructured":"Consulta de Registros Sanitarios (COFEPRIS), Xospata\u00ae (gilteritinib) 40.00 mg tablet [Health Registry Data], Astellas Pharma Tech Co., Ltd., 2023. Available from: https:\/\/tramiteselectronicos02.cofepris.gob.mx\/BuscadorPublicoRegistrosSanitarios\/BusquedaRegistroSanitario.aspx Accessed April 28, 2026."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101229_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ejh.13205","article-title":"Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: a medical chart study","volume":"102","author":"Griffin","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101229_bib0013","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101229_bib0014","unstructured":"National Comprehensive Cancer Network (NCCN), NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for acute myeloid leukemia V.4.2023 2023. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf Accessed April 28, 2026."},{"key":"10.1016\/j.ctarc.2026.101229_bib0015","unstructured":"Consulta de Registros Sanitarios (COFEPRIS), Venclexta\u00ae (venetoclax) 50.00 mg tablet [Health Registry Data], AbbVie Inc, 2018. Available from: https:\/\/tramiteselectronicos02.cofepris.gob.mx\/BuscadorPublicoRegistrosSanitarios\/BusquedaRegistroSanitario.aspx Accessed April 28, 2026."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101229_bib0016","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41375-024-02382-9","article-title":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia","volume":"38","author":"Wang","year":"2024","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101229_bib0017","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.3390\/cancers16234028","article-title":"Salvage therapy with second-generation inhibitors for FLT3 mutated acute myeloid leukemia: a real-world study by the CETLAM and PETHEMA groups","volume":"16","author":"Vives","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.ctarc.2026.101229_bib0018","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101229_bib0019","doi-asserted-by":"crossref","first-page":"279.e1","DOI":"10.1016\/j.jtct.2022.12.013","article-title":"An analysis of the worldwide utilization of hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"29","author":"Tokaz","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101229_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2022.2158015","article-title":"Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America","volume":"28","author":"G\u00f3mez-De Le\u00f3n","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101229_bib0021","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1080\/16078454.2022.2156737","article-title":"Hematopoietic stem cell transplantation activity in Mexico during the COVID19 pandemic: on the way to recovery","volume":"27","author":"G\u00f3mez-De Le\u00f3n","year":"2022","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101229_bib0022","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.bbmt.2017.07.010","article-title":"Outcomes of hematopoietic stem cell transplantation at a limited-resource center in Mexico are comparable to those in developed countries","volume":"23","author":"Rodriguez","year":"2017","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.ctarc.2026.101229_bib0023","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101229_bib0024","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00277-022-04895-8","article-title":"Gilteritinib monotherapy for relapsed\/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis","volume":"101","author":"Shimony","year":"2022","journal-title":"Ann. Hematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:05Z","timestamp":1790913485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"alternative-id":["S2468294226001401"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101229","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment landscape, outcomes, and healthcare resource utilization in FLT3+ relapsed\/refractory acute myeloid leukemia in Mexico","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101229"}}